The term acute-on-chronic liver failure (ACLF) was introduced into hepatological practice over the past decade. Definitions of ACLF have emerged from the European Association for the Study of the Liver (EASL) alone, as well as in conjunction with the American Association for the Study of the Liver, and from the Asian Pacific Association for the Study of the Liver (APASL). (1, 2) The suggestion is that it is a discrete condition caused by an acute illness in patients with cirrhosis leading to failure of at least 1 organ. However, ACLF means different things to different people and nothing to some. The authors of the large study from the Acute-on-Chronic Liver Failure and Cirrhosis (CANONIC) acknowledge at the outset that "definitions differ greatly from each other and were developed in a theoretical rather than experimental basis." (3) A joint meeting of American and European experts agreed on a definition of ACLF as being "an acute deterioration of liver function in patients with cirrhosis which is usually associated with a precipitating event and results in the failure of one or more organs and high short-term mortality." (1) This concept is vague and open to multiple interpretations, and the EASLchronic liver failure consortium subsequently attempted to flesh out details of the condition in pursuit of a more specific definition. (3) The APASL definition of ACLF is "an acute hepatic insult manifesting as jaundice (serum bilirubin > 5 mg/dL) and coagulopathy (international normalized ratio [INR] > 1.5), complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed liver disease." (2) This definition is more precise and, because it is essentially the classical causes of acute liver failure (ALF) superimposed on cirrhosis, is conceptually easier to understand and recognize. ALF sets the standards by which ACLF needs to be assessed in terms of clinical utility and functionality. It is defined, in the absence of previous liver disease, as an acute insult to the liver leading to liver failure manifest by coagulopathy and encephalopathy. The precise trigger is not always overt, and the condition exhibits considerable heterogeneity. Despite this, it is clinically recognizable as a discrete entity with well-developed management plans which integrate emergency liver transplantation. The overall survival rates are now on the order of 80%. A perceived clinical utility of the ACLF categorization includes accelerated access to liver transplantation as currently afforded to patients with ALF. A fundamental prerequisite for a policy change justifying that status would be an equivalent robust framework for diagnosis and prognostication of ACLF.
Acute-on-Chronic Liver Failure and Cirrhosis Study
The CANONIC study was performed in Europe by the EASL-CLIF consortium. (3) The study enrolled 1343 patients hospitalized with acute decompensation of cirrhosis. Although it was acknowledged that an agreed-upon definition of ACLF did not exist, the group was able to characterize 415 patients as having the condition. These 415 patients were then compared with the other 928 patients, and parameters that were statistically different were deemed to define the condition. The distinguishing features were organ failure, high mortality rate, age, precipitating events, and systemic inflammation. Specific comments in relation to each of these are as follows:
1. The definition of qualifying organ failure was diffuse and included renal failure in isolation, 2 or more organ failures, single organ failure with a serum creatinine ranging between 1.5 and 1.9 mg/dL, and single organ failure other than kidney with mild-tomoderate hepatic encephalopathy. The precision that this definition offers is matched to the lack of simplicity that is attractive to clinicians. 2. It is not useful to integrate an anticipated high mortality rate into the definition of a condition if it cannot be predicted with precision at the time of diagnosis. In this study over two-thirds of patients defined as having the condition survived at least 28 days, which is a time interval that would be expected to see resolution of that event by means of survival, death, or liver transplantation. The observed 28-day mortality rate was actually double the expected 15% rate which in itself is of limited clinical utility. The conventional approach, which is to define a condition and then describe the natural history and prognostic factors, would be a more persuasive way to develop a new entity. 3. The principle of including age in a definition of a condition that spans a large section of the population is also unsound. Furthermore, the mean age of 58 years in patients with the condition may be considered statistically different from the 56 years in those without ACLF, but this observation has no clinical relevance. 4. Factors precipitating ACLF include some common to the APASL definition, like viral hepatitis or alcohol, but also some that are very familiar as features of decompensating cirrhosis, like sepsis and renal dysfunction. Even though the concept of ACLF embraces a precipitating event, no such event was identified in 44% of patients considered to have ACLF. Furthermore, neither the presence/absence nor the type of precipitating event was found to be related to the rate of mortality. This begs the question as to why precipitating events were promoted as part of the definition set.
Gastrointestinal bleeding is one of the most important acute events in patients with cirrhosis, and it is inextricably linked to a risk of decompensation. It would be expected to feature prominently, but the analytical approach adopted in this study would suggest that it should not be considered a precipitant of ACLF because it occurred with a similar frequency in patients not considered to have the condition. This will seem counterintuitive to many clinicians. 5. White cell count and C-reactive protein levels were the inflammatory markers included in the definition, but neither parameter had a discriminatory level. The mean white cell count in patients with ACLF was actually in the normal range (9.7 3 10 9
). There was also very considerable overlap in C-reactive protein levels between the two groups. Systemic inflammatory response (SIRS) was not assessed in this study but has been linked to ACLF in other publications. (4) The components of SIRS are simple, and a patient with a pulse rate of 91 beats/minute, body temperature of 38.1 8C, respiratory rate of 21 breaths per minute, and a white cell count of 3500/mm 3 would be considered as having SIRS. This profile is frequently encountered in patients with cirrhosis and, as in other clinical settings, may be too sensitive and nonspecific to predict a complicated clinical course. (5, 6) CLIF-Sequential Organ Failure Assessment (SOFA) score was developed by the CANONIC group based on a combination of published data and the clinical experience of the authors. ( 3) It combines serum bilirubin, serum creatinine and INR with encephalopathy and circulatory and respiratory function. The CLIF-SOFA score was retrospectively validated in a cohort of 971 patients with cirrhosis. (7) However, a large prospective study from the CLIF group, presented at the 2017 International Liver Transplant Meeting, failed to demonstrate any advantage of CLIF-SOFA over Model for End-Stage Liver Disease (MELD) in predicting mortality (C. J. Karvellas, personal communication).
Among the requirements to define a new condition are tight diagnostic criteria and the development of prognostic criteria in training and validation sets. These have not been met in the case of ACLF.
Acute Alcoholic Hepatitis
The inclusion of alcohol as a precipitant of ACLF encroaches on the territory of the diagnostic entity of acute alcoholic hepatitis. This group of patients is well characterized and clinically easily recognizable. Diagnostic criteria are agreed and prognostic models are widely used in clinical practice. There is also enough confidence in the understanding of the condition to permit the use of emergency liver transplantation in highly selected patients. (8) There seems little merit in drawing some of these patients into an alternative characterization of their condition with less clearly defined management pathways.
Conclusion
ACLF is still not definable as a discrete entity within the spectrum of patients with acute decompensation of cirrhosis. I see it as neither an apple, nor an orange, nor a banana, but as a bowl of fruit salad biased to contain more of the preferred fruit. If the concept is strong, does it matter that the finer details have yet to be worked out? I believe it does for both scientific and clinical reasons. A tight definition is needed to standardize research and development of the condition. The condition should be recognizable to all and not just to enthusiasts. Research should enlighten with confidence rather than reinforce opinion developed on weak foundations.
It may be the case that the EASL-CLIF concept is a work in progress that will mature into a clinically robust clarification of a group of patients who require a distinct management plan. This is another requirement to give the definition of the condition clinical relevance. Access to emergency liver transplantation is a good example of a management option to help crystallize thinking on the functionality of ACLF. The gap between the current status of ACLF and the clarity and stringency of the control of access to emergency transplantation in ALF is vast. Until there are significant improvements in definition and prognostication of ACLF, MELD will remain the gateway to liver transplantation.
Methinks, the emperor has new clothes!
